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Computational models for  
transplant biomarker discovery
Anyou Wang and Minnie M. Sarwal *
Department of Surgery, Division of MultiOrgan Transplantation, University of California San Francisco, San Francisco, CA, USA
Translational medicine offers a rich promise for improved diagnostics and drug discovery 
for biomedical research in the field of transplantation, where continued unmet diagnostic 
and therapeutic needs persist. Current advent of genomics and proteomics profiling 
called “omics” provides new resources to develop novel biomarkers for clinical routine. 
Establishing such a marker system heavily depends on appropriate applications of com-
putational algorithms and software, which are basically based on mathematical theories 
and models. Understanding these theories would help to apply appropriate algorithms to 
ensure biomarker systems successful. Here, we review the key advances in theories and 
mathematical models relevant to transplant biomarker developments. Advantages and 
limitations inherent inside these models are discussed. The principles of key computational  
approaches for selecting efficiently the best subset of biomarkers from high-dimensional  
omics data are highlighted. Prediction models are also introduced, and the integration of 
multi-microarray data is also discussed. Appreciating these key advances would help to 
accelerate the development of clinically reliable biomarker systems.
Keywords: transplant, model, theory, computation, bioinformatics, rejection
introduction
In the new era of biomedical research, it is being increasingly recognized by funding agencies and 
journals that traditional hypothesis-driven research alone cannot provide the rapid and incremental 
advances needed to change the current clinical practice management for transplant patients, so as 
to positively impact long-term graft outcomes. In addition, given that organ transplantation is an 
orphan disease, there are few if any focused efforts for discovery of new immunosuppressive drugs 
for transplant recipients. In fact, the number of Food and Drug Administration (FDA) approved 
drugs has been relatively constant to about 20 drugs per year, yet the cost of drug discovery has 
ramped up ($138 million in 1975 to $1.3 billion in 2006), and the rate of new drug production by a 
pharmaceutical company generally follows a Poisson distribution and is constant (about 2–3 drugs 
per year at most) (1). This constant rate of output is often blamed on the traditional hypothesis-driven 
research model, primarily because hypotheses derived from complex experimental models often do 
not translate to human pathology. Hence, there is a growing need to harness “big data” at the RNA/
protein/metabolite/antibody/DNA level to get novel insights into interlinked global processes that 
have been hitherto poorly understood. With this direction, comes the companion need to develop 
and apply the right computational tools to harness this data and interlink it to the entire electronic 
medical record (EMR) in an identified, regulated process.
Although short-term survival rates of grafts have increased, long-term graft survival rates have 
shown little improvement (2, 3). Five-year graft survival for transplanted organs varies from 43% 
for lung to 78% for kidney, highlighting the need for improved analysis of post-transplant injury 
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pathways. There is a desperate urgency to advance the field of 
organ transplantation through improved monitoring by (a) the 
discovery of informative biomarkers, specific and sensitive to 
phenotypes of injury and acceptance, and (b) through improved 
algorithms and/or drugs for treatment with targeted efficacy and 
reduced toxicity (4, 5). Many single gene/protein pathway studies 
have shown associative and mechanistic insights into animal and 
restricted human sample studies, but the field has stalled with 
regard to the additional exponential insights needed at a genome-
wide level to develop significant improvements in biomarker 
discovery for diagnosis/prediction and to evaluate the role of 
novel pathways for improved rational drug design as it applies to 
organ transplantation. In this review, we focus on the application 
of different computational approaches to mine high-dimensional 
human data in transplantation with a view to changing current 
clinical practice and patient management. Some of the critical 
requirements that the transplantation process needs to fulfill with 
this meta-data approach are highlighted in Figure 1.
Biological experimental tools that explore genome-wide profil-
ing referred as “omics” provide promising pathways to investigate 
transplant biology, and they have been increasingly applied in 
transplantation, with the number of generated data tripling over 
last decade (Figure 2). These omics technologies (e.g., functional 
genomics for RNA analysis, proteomics for protein and peptide 
analysis, metabolomics for metabolite analysis, and antibiomics 
for HLA- and non-HLA-antibody analysis) also provide “big 
data” that contains high-dimensional variables. Harnessing the 
“big data” to low dimensional variables could generate small 
sets of biomarkers for diagnostic tools, which detect and predict 
FiGURe 1 | Transplant fields require computations. The boxes show the areas of investigation needed by translational computational methods to advance 
organ transplant management. Figure adapted from Ref. (6).
transplant injury as well as discriminate different causes of 
injuries. However, these omics data are generally complex, due to 
its inherent high-dimensional complexity, platform differences, 
hybridization variations, and different data scales. These com-
plexities challenge scientists to directly extract biologically valid 
and clinically useful information by selecting, generating, and 
using the appropriate computational tools to meet the demands 
of the composition of the input data.
Decomposing the complex omics datasets to derive biomark-
ers often requires customization of computer algorithms and 
software. Limitations and pitfalls inherent inside these software 
tools, such as biased p-value estimation, over-estimated predic-
tion accuracy, could derail the successful selection of biomarkers 
due to enhanced false positives and negatives. Thus, applying 
appropriate algorithms to decompose the complexity requires 
an understanding of the theories and principles behind these 
algorithms. Here, we review key advances of theory and compu-
tational models relevant to transplant biomarker development. 
Understanding these key advances would help to master the 
wave of biomarker development and to develop novel reliable 
biomarker systems (4, 7–9).
High-Dimensional Data Applications in 
Transplantation
Gene expression microarrays have been the most commonly 
used high-throughput technology in transplantation (10, 11). 
Microarrays were applied to biomedical science in 1995, and 
the first landmark study of kidney biopsy microarrays was 
FiGURe 2 | Pubmed publications on transplant genomics and proteomics paper over last 10 years. Data were extracted from Pubmed by searching 
transplant and genomics or transplant and proteomics.
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published in 2003 [Sarwal et al. (12), NEJM], uncovering for the 
first time molecular heterogeneity in acute rejection that was 
far greater than previously understood by histology alone and 
a pivotal role for B cells in steroid-resistant late post-transplant 
rejections occurring secondary to treatment non-adherence. 
There are an increasing number of human studies in the public 
domain profiling biopsy, bronchoalveolar lavage, and blood 
and urine samples from different organ transplant recipients, 
with phenotypes defined by matching graft biopsies as acute 
rejection, chronic injury, recurrent glomerulonephritis, viral 
nephritis, operational and induced tolerance, and drug toxicity. 
Transcriptional profiling of peripheral blood as a correlate of 
intragraft events has been successfully applied in the IMAGE 
Study in heart transplantation (13) and in the SNSO1 (14) 
and AART (15) studies in kidney transplantation and for the 
detection of chronic graft vs. host disease in bone marrow 
transplantation (16). Pathogenesis-based transcripts (PBT) 
expression panels have been inferred from mouse experiments 
and applied to human transplant expression patterns in an 
effort to develop correlates of histopathological lesions in renal 
transplant biopsies (17).
A major challenge in transplantation is the life-long admin-
istration of immunosuppressive drugs with multiple side effects. 
Calcineurin inhibitors are associated with nephrotoxicity, which 
in turn can contribute to long-term graft failure, along with 
opportunistic infections. To better understand the mediators 
of calcineurin inhibitor toxicity, selected patients from the 
BENEFIT trial (Vincenti, NEJM), had their 1-year protocol 
biopsies profiled against gene-sets selected after loading cyclo-
sporine and tacrolimus on renal proximal tubular cells, as the 
in vitro model of calcineurin inhibitor toxicity. Patients receiving 
Belatacept and no calcineurin inhibitor agents demonstrated 
more immune reactivity, but reduced expression of profibrotic 
genes and increased expression of solute transporter genes, corre-
lating with the preserved renal architecture seen in these patients 
(18). To better understand how to optimally dose patients with 
immunosuppressive drugs, operationally tolerant patients were 
profiled (19), and informative genes were used to identify patients 
on full dose immunosuppression that may benefit from safe 
immunosuppression wean (19), after controlling for multiple 
clinical variables and confounders.
High-throughput technologies have also been expanded to 
study the role of microRNAs (miRNAs) in graft rejection in 
peripheral blood (20) and the allograft (18), and suggests that 
intragraft changes in miRNA levels are explained by the burden 
and composition of infiltrating cells in the course of injury.
The introduction of high-density protein arrays as allowed 
for the evaluation of serological responses to ~9,000 human 
full-length proteins on a single slide. This technology was used 
to understand the differential immunogenicity of different tissue 
compartments of the transplanted kidney (21), and identified that 
the renal outer cortex, glomerulus, and the deep pelvis antigens 
mount new autoantibody responses after organ engraftment, most 
of which may not be pathogenic. In addition, this technology was 
also used to evaluate the identity of novel non-HLA antibodies 
in patients with HLA-antibody-negative acute renal transplant 
rejection, and identified a novel target, Kinase C-ζ (PKCζ), as a 
dysregulated epitope in severe allograft injury (22). Additionally, 
using protein microarrays, Angiotensinogen and PRKRIP1 were 
identified as biomarkers of chronic kidney injury, with correlative 
results with hypertension in patients with high-antibody titers. 
These results suggested for the first time that autoantibodies are 
raised against previously unknown antigenic targets in the trans-
planted organ, which are likely exposed to the immune system of 
the recipient in the process of cellular damage in the organ (23).
Recent advances in small molecule identification technologies 
(e.g., mass spectrometry, surface enhanced laser desorption/ioni-
zation, liquid chromatography/mass spectrometry, nuclear mag-
netic resonance) have given rise to the application of proteomics, 
peptidomics, and metabolomics to transplantation. Urine is a rich 
biofluid source for biomarker discovery in organ transplantation. 
Shotgun proteomics provides us with a map the entire urinary 
proteome (24) in health and transplant injury states. Smaller 
fragments of the urinary peptidome, consisting of degraded 
byproducts of intact proteins by enzymatic cleavage, also provide 
insights into the perturbations in chemical balance during kidney 
injury (25, 26). Metabolomics has been used for identifying graft 
injury as well as for monitoring drug toxicity (27–29).
September 2015 | Volume 6 | Article 4584
Wang and Sarwal Mathematical models for transplant markers
Frontiers in Immunology | www.frontiersin.org
Computational Challenges and 
Approaches for Selecting Biomarkers 
from High-Dimensional Data
The integration of hypothesis generation by high-dimensional 
data analysis is poised to fulfill the current unmet needs in 
organ transplantation, which relates to poor long-term survival 
despite improvement in short-term outcomes, the need for 
life-long immunosuppressive medications and their associated 
morbidities, and the lack of non-invasive markers for monitor-
ing and predicting graft injury, superior to current standards of 
monitoring. Computational biology expands from the traditional 
molecular biological method of studying pair-wise interactions 
into a network-based approach by integrating individual compo-
nents to model a complex system, thus beginning to understand 
disease at the level of regulatory pathways in tissues and organs, 
even in whole organisms, while also accounting for dynamics 
within regulatory networks. A large number of computational 
approaches have been developed to generate co-expression 
networks from protein binding data (30), functional annotations 
(31), and drug activity (32). Using these approaches, it has been 
shown that such networks have properties that are not otherwise 
discernable from the relations themselves, and have preferential 
connectivity that results in “hub” nodes, which are molecules that 
connect to a larger number of other molecules (33).
To date, a large number of biomarkers have been identified 
for various post-transplant conditions as markers of an ongoing 
injury (effect markers) or related to the actual causes of the injury 
(causal markers). Development of new drugs that reduce drug 
toxicity and chronic rejection requires identification of causal 
markers that can be targeted for novel therapeutics. The use of 
systems and computational biology is the critical next step for 
deeper understanding and the identification of causal markers of 
graft injury in transplantation.
One of the reasons for the limited impact of the high-through-
put studies in transplantation relates to low number of individu-
als and samples used resulting in lack of sufficient independent 
validation. As described in our previous review (6), searching the 
NCBI GEO for microarray studies in humans described with the 
term “transplant” yields 69 experiments, of which only 16 have 
more than 50 samples and only 6 have more than 100 samples. 
These numbers are even more disappointing when put into the 
context that these experiments are divided among four different 
organs (lung, kidney, liver, heart) studying at least three different 
conditions (acute rejection, chronic rejection, tolerance). The 
sample limitations relate to sample availability and assay cost, 
both of which truncate greater enrollment. We addressed the 
sample availability shortcoming by performing meta-analysis by 
integrating smaller independent experiments, and customized 
algorithms were generated to deal with experiment-specific 
technical biases, such as microarray platform or hybridization 
protocol (6, 34). This approach allowed for the identification of a 
core of 12 genes (BASP1, CD6, CD7, CXCL9, CXCL10, INPPD5, 
LCK, NKG7, PSMB9, RUNX3, TAP1, ISG20), called the common 
immune response module, which was a similarly dysregulated 
set of genes in acute rejection across tissue source; these genes 
were all upregulated in kidney, heart, liver, and lung rejection 
across 236 microarrays downloaded from GEO. Their biological 
relevance in graft rejection was further tested by repositioning 
two drugs against LCK (Dasatinib) and CXCL10 (Atorvastatin) 
in a murine heart transplant model of rejection; thus suggesting 
that FDA-approved drugs for indications other than transplant 
immunosuppression may be repositioned across the remainder 
of the gene-set to identify new drug targets for organ transplant 
recipients. In another example of an integrative analysis, Chen 
et  al. performed a meta-analysis using three transplant RNA 
microarray data sets from biopsies with kidney and heart acute 
rejection (35), and then the corresponding significant proteins 
(inferring gene/protein 1:1 mapping) coded for by these RNA 
were then screened as potential blood markers for acute rejection. 
This approach confirmed that three proteins (PECAM1, CD44, 
and CXCL9) were significantly over-expressed in blood samples 
in both kidney and heart transplant patients. These integrative 
approaches demonstrate that integration of data sets can reduce 
biological bias across experiments, experimenters, platforms, and 
tissue source, while allowing for the generation of novel hypoth-
eses and drug repositioning.
Data integration can also be performed across different types 
of molecular measurements. Li et  al. integrated antibody-level 
measurements from a protein array with renal compartment-
specific gene expression data (21) and demonstrated that 
post-transplant serological responses observed using protein 
microarrays were specific to the transplanted organ and to spe-
cific organ compartments.
The efficient selection of biomarkers to limit false negatives 
and false positives is another challenge for high-dimensional data 
analysis. A typical microarray experiment produces approximately 
50,000 data points per sample. An experiment with 50 samples will 
produce more than 2.5 million data points. Millions of data points 
are generated by SNP genotyping platforms for thousands of sam-
ples in a typical genome-wide association study. The amount of 
data generated increases again exponentially for next-generation 
sequencing population studies. Incorporation of computational 
skills into the curricula of transplantation training program needs 
to be a high priority, to arm the next-generation clinician scientist.
Various methods are used to limit false-positive/negative sig-
nals and reduce variables. These mainly use stepwise regression 
models (36, 37), principal component analysis (PCA) (38, 39), 
T-statistic, and correlation to clinical variables (7, 8, 40–43).
Stepwise-Based Models
Traditional Stepwise Methods
Many regression models are available to select a particular set 
of independent variables and the commonly used methods are 
stepwise techniques (36, 37). Traditional stepwise selection 
alternates between forward and backward regression selection, 
in which variables are added or removed that meet a selection 
criteria setting for entry or removal, until a final subset of vari-
ables make the model saturated. However, this stepwise method 
has essential problems. It applies methods intended for one single 
hypothesis test to many tests, leading to results biased to a certain 
degree, such as higher in R2 (explained variation/total variation), 
lower in standard errors and p-values than the actual values, and 
as models they can be complex to develop.
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Vorlat et al. used stepwise multiple regression and identified 
B-type natriuretic peptide (BNP) and age as the most important 
factors in evaluating outcomes after heart transplantation, after 
evaluating many variables, such as body mass index, age, BNP, 
norepinephrine dose, gender, and total ischemic time (37).
Lasso (Least Absolute Shrinkage and  
Selection Operator)
Lasso (least absolute shrinkage and selection operator) (44) is a 
penalized regression method for shrinkage and variable selection, 
and uses the equation:
 
∑∑ ∑− β

 + λ β= = | |1
2
1
y xi ij
j
j
i
n
j
j
p
 
  i = 1, 2, …, n (n equivalent to sample size);
  j = 1, 2, …, p (p equivalent to omics gene number);
  yi = response variable of sample i, βj = coefficient for gene 
j, j = 1, 2, …, p, and xij = observation value of sample i and 
gene j.
Lasso estimation actually introduces a penalized constraint 
to minimize the usual sum of squared errors to get solution. 
This penalization is estimated by ∑ β ≤ s| | ,j  sum of the absolute 
coefficients.
If s is set to a large number, it does not affect Lasso estimation 
that actually acts as a usual multiple linear least squares estimates. 
Then, a large number of genes might be selected as biomarkers. 
However, if s is small (s ≥  0), Lasso works as shrunken least 
squares regression and then only a few genes would be selected 
as biomarkers. Lasso has several limitations. For example, the 
gene number (p) is usually large and sample size (n) is small. In 
this case, at most n genes are selected by Lasso before the model 
saturates. In addition, Lasso tends to select the biomarker with 
greater variance (44) and it might likely ignore some important 
genes in a correlated group.
Elastic-Net
To overcome the limitations existing in Lasso, elastic-net adds an 
additional quadratic part ∑ β ≤2 tjj  to the penalization to make it 
work for both variable selection and shrinkage (45). Many modi-
fications have been made to improve its prediction performance. 
Elastic-net and lasso are arguably the best methods so far for 
shrinkage and biomarker selection. Lasso and elastic-net were to 
select a best subset of 17 genes as biomarkers to predict the most 
informative acute rejection blood-based biomarkers (15).
Modified t-Statistic Methods
Prediction Analysis of Microarrays
Prediction analysis of microarrays (PAM) has been commonly 
applied in transplant (40, 46, 47). PAM uses the following equa-
tion to determine if a gene is significant for classification:
 ( )
=
−
+ 0
d x x
w s sik
ik i
k i  
where = −(1/ 1/ )1/2w n nk k
It actually looks like t-statistic formula, where wk ×  si is the 
standard error of the numerator. The only modification is to add 
s0 as a fudge factor to avoid very large statistics for very small 
standard errors. Thus, PAM is a modified t-statistic to measure 
the difference between the mean of gene i in class k with the over-
all mean of gene i. A gene with a statistic of large absolute value 
discriminates one class from the rest. PAM then selects significant 
genes by then shrinking the dik toward zero.
This measurement in PAM actually shrinks each gene toward its 
overall mean cross classes. After this shrinkage, all class centroids 
become more similar to each other than before. This might not 
help to improve the overall discriminant accuracy in omics data.
Reeve et al. used PAM to select the most significant genes from 
186 microarrays to build a classifier system to predict acute rejec-
tion. These genes are mostly associated with interferon-gamma-
inducible or cytotoxic T-cell associated, such as CXCL9, CXCL11, 
GBP1, and INDO (47).
ClaNC
To circumvent the PAM limitations, an alternative classifier called 
ClaNC (42) has been developed. ClaNC uses standard statistics to 
select genes and does not shrink centroids, and it also selects class-
specific gene and allows a gene to be active only in one class. Kurian 
et al. used this algorithm to select 200 biomarkers from genome-
wide gene expression profiling and created a discriminant system 
for classifying three phenotypes in kidney transplantation (48).
Principal Component Analysis
Principal component analysis method selects biomarkers based 
on an eigengene score (38), score |cor= x Ei , | ,( ) ( )| cor , |x Ei  is 
the absolute value of Pearson correlation coefficient, where xi is 
a vector of gene i, and E is a eigenvalue.
Genes Selected by Correlating with  
Clinical variables
A subset of genes can also be selected by correlating gene expres-
sion level and clinical variables, such as patient survival or graft 
loss. This correlation can be measured by univariate Cox propor-
tional hazards scores that derived from Cox regression model. 
Genes that pass the interquartile range (IQR) filter are considered 
as significant (40, 41).
evaluation of Models and Biomarkers 
Requires Robust validation
Many biomarker systems published to date for transplant fail in 
the real world, partially due to lack of robust model validation. 
Models usually should be subject to cross-validation, a technique 
for evaluating the performance of predictive models, like linear 
models for discriminating acute rejection against stable samples, 
with the use of independent samples in the different subsets. 
Different types of cross-validations are available. Repeated random 
sub-sampling validation randomly splits all samples into subsets of 
samples, a training set, and validating set. The training subset is 
used to fit a model and the validating set is for examining predictive 
accuracy. A large iteration of splits (e.g., 10,000) is usually run to 
avoid splitting sample bias. The accuracy is calculated by the aver-
age of all iterations. k-fold cross-validation randomly splits total 
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samples into k subgroups with equal size. One out of k subgroups 
is treated as testing validation and the remaining k − 1 subgroups 
are used as training data to train models. The whole process is run 
k times (k folds). Each time, each of the k subgroups is used as 
validation but each group is used only once. The sensitivity and 
specificity can be calculated by combined result from each run. 
We have extensively used these systems of study (15, 19), and 
the process of robust cross-validation has also been extensively 
reviewed in a recent publication by Roedder et al. (49).
The binary classified performance of an entire biomarker 
system should typically be evaluated by receiver operating char-
acteristic curve, ROC curve. ROC is a graphical plot of the true 
positive rate (sensitivity) against specificity or false positive rate 
(1-specificity) at various threshold settings. The sensitivity is equal 
to the proportion of correctly classified positive observations, and 
the specificity is calculated as the proportion of correctly classi-
fied negative observations. Area under the curve (AUC) serves as 
estimated index of overall accuracy and serves a useful practice 
to compare different ROCs, and it is usually plotted within ROC 
curve. The biomarker panels developed for graft rejection and 
tolerance in recent studies provide ROC curves of >85% (15, 19).
Prediction Models for Biomarker  
Risk Analysis
One of the most interesting goals in developing biomarker systems 
is to predict and monitor the phenotype outcome of transplanta-
tion. For example, selecting biomarkers from short-term data (e.g., 
3 months biopsy profiling) may be associated with a phenotype of 
long-term (e.g., 1-year graft chronic injury) outcomes. Predictive 
models have been applied to reach this purpose. Although all 
machine learning models have predictive functions, such as 
Support Vector Machine (38, 39) and LASSO described above, 
two out of them, linear discriminant analysis (LDA) and logistic 
regression, have been widely applied in transplant biomarker 
systems to classify the discrete classes of variables (40, 48, 50, 51).
Linear Discriminant Analysis
Linear discriminant analysis has been widely applied to trans-
plant biomarker development (40, 48). LDA is a classifier (52) 
that classifies samples to their nearest given centroid. Assuming 
that we have k classes with prior probabilities πk, then LDA can 
be defined below:
 
µ µ pi{ }( ) ( ) ( )= − Σ − −−k Ty x xˆ arg min 2logk k k1  
where − 2x u  is the square of the Mahalanobis distance between 
sample value (x) and centroid or mean (u).
Logistic Regression
Logit link function can be understood as follows:
 
β β β β=
−
= + + + +odds 
p
p
x x xlog log
1 k k0 1 1 2 2  
  p = probability of one phenotype; =
−
odds
1
p
p
  xi = ith biomarker value, i = 1, 2, …, k.
The left side of logit link function above can be signed as Y, 
and then this function can be simply written as Y = β0 + βX, so it 
can actually be understood as a linear regression. The phenotype 
variable in logit could be binary value (e.g., AR vs. non-AR) or 
multinomial.
Correlation
Besides machine learning, other mathematical methods have also 
been employed to establish quantitative biomarker system. Here, 
we introduce one, kSORT (15), based on Pearson correlation 
coefficients of multiple genes (12 genes). Genes for kSORT were 
selected by Lasso and elastic-net. Binary classification of AR vs. 
non-AR was based on accumulated scores. These scores were 
accumulated from running correlation for 13 times with 12 gene 
panels. The score was assigned as 1 (if greater correlation to AR) 
or −1 (if greater correlation to non-AR). After 13 runs, the final 
score of a sample would be in the range from −13 to 13. This rank 
is then used as an index of a risk factor for acute rejection.
Data integration Strategies
Many omic experiments have been performed with different 
platforms by different laboratories. These omics data cannot be 
treated as a single experiment and a meta-analysis strategy should 
be applied to integrate these data to get a panel of prioritized 
genes. Several techniques and theories have been proposed (34, 
53, 54). Here, we only briefly described four methods employed 
in transplant biomarker development.
Normalization and Batch effect Removal
For combining small set of microarray data with a big data set, 
normalization can be performed using Lowess (locally weighted 
scatterplot smoothing) or Loess (55) (later generalization of 
Lowess), and then batch effect should be removed. Lowess is a 
non-parametric regression method for fitting a smoothing curve 
to a dataset by combining regression models and weights of local 
neighbors. It splits the microarray intensity curve into a series 
of windows by a given window size and then performs regres-
sion locally with nearest weight to smooth the curve. A larger 
window size produces a smoother curve, and a smaller window 
size generates more local variation. After normalized, batch effect 
can be removed by using empirical Bayes methods (56) before 
combining the data (57).
Frozen Robust Multiarray Analysis
Robust multiarray analysis (RMA) is a pre-processing algorithm 
that pre-processes microarray data by background correction, 
quantile normalization, and summarization in a modular way by 
fitting the normalized data with models. It is widely used, but 
RMA cannot be used in clinical data directly because these data 
are normally in small batches, and clinical samples are normally 
processed individually and separately and they are comparable. 
Therefore, a modified RMA, frozen robust multiarray analysis 
(fRMA), has been proposed. fRMA computes and freezes probe-
specific effects and variances of a dataset, and with new data sets 
coming, these precomputed and frozen info are used in concert 
with those from the new coming microarrays to normalize and 
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summarize the data. Thus, it provides a way to combine data 
analyzed individually or in small batches (53).
When merging multiple datasets, the raw data (e.g., CEL file 
for Affymetrix array) are usually used in order to pre-processing 
all data (e.g., outlier deletion and normalization) with the same 
algorithm and the similar criteria. If multiple probes exist for a 
transcript, the mean of probes is used to represent the expression 
level of this transcript. The genome annotation IDs (e.g., refGene 
IDs) universal for all platforms are usually employed to combine 
the data.
p-value Meta-Analysis
p-value meta-analysis uses Fisher’s method to combine the 
squares of the p-values as defined below (34):
 
∑χ ( )= −
=
2 log2
2
1
pk
i
k
i
 
where k = experiment number, pi is devised from each experiment. 
This p-value combination would generate a list of genes with meta 
p-value for each gene. Genes with up- and down-regulation is 
separated into two groups during combining p-value but only one 
with minimum p-value is selected. The meta p-value can then 
further be corrected by multiple hypothesis testing to obtain 
adjusted p-value. The final adjusted p-value is used to prioritize 
genes. Lower in adjusted p-value ranked in the top.
Fold-Change Meta-Analysis
Another prioritized gene method is based on fold-change meta-
analysis as defined below (34):
 
( )
( )=
+ + +
+ + +
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f
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where,
  fi = fold-changes in sample i;
  wi = reverse variance of the fi.
It should be noted that meta-analyses might produce different 
rank prioritizations of genes differentially expressed across stud-
ies, and the final biological relevance of the selected genes also 
becomes important in the final gene selection.
Conclusion and Future Directions
In order to take our understanding of injury mechanisms in 
organ transplantations to the next level, integration of molecular 
measurement data from different experiments and different 
technologies is required. Furthermore, these integrated data 
need to be analyzed at a global, systems biology level to identify 
better diagnostic and therapeutic markers. Predictive biomark-
ers should cover diverse genetic and epigenetic backgrounds. 
Clinical and pathology-based variables should be considered as 
confounding variables during biomarker development. Next-gen 
sequencing will provide much higher resolution than microar-
rays to get insights into the diversity of injury and patient-specific 
responses. With new advances in mathematical theories, a new 
biomarker system may include many variables from different 
biology aspects, such as genetics, epigenetics, clinical variables, 
and pathology.
Biomarker discovery suffers from difficulties in selecting 
“noise” form “true biology” as this discovery relies on human 
studies and human samples, which are inherently associated with 
sample and tissue variation, and often result from the use of mul-
tiple measurement platforms, with experimental methodology 
variations, all of which challenge the process of robust biomarkers 
TABLe 1 | Primary computational algorithms for transplant biomarker discovery.
Name environment Features and 
functions
Limitations Availability web resources
Biomarker selection
Traditional stepwise methods R/SAS Stepwise regression High R2, low SE Free/commercial www.r-project.org, www.sas.com
LASSO and Elastic-net R/SAS Shrinkage and 
biomarker selection
Model could be saturated for 
Lasso when simple size is small
Free/commercial www.r-project.org, www.sas.com
Prediction analysis of 
microarrays (PAM)
Excel/R Shrinkage and 
biomarker selection
Might not improve the overall 
discriminant accuracy
Free http://statweb.stanford.edu/~tibs/PAM/
ClaNC R Classification and 
biomarker selection
Limited improvement in 
discriminant accuracy
Free http://www.stat.tamu.edu/~adabney/clanc/
Principal component analysis R/SAS Classification and 
biomarker selection
Sometimes it is hard to interpret 
data
Free/commercial www.r-project.org, www.sas.com
Prediction models
Linear discriminant analysis 
(LDA)
R/SAS Classification and 
prediction
Linear Free/commercial www.r-project.org, www.sas.com
logistic regression R/SAS Classification and 
prediction
Requires large sample size Free/commercial www.r-project.org, www.sas.com
Data integration strategies
Normalization and batch 
effect removal
R Pre-processing Might not fit clinical data directly Free https://www.r-project.org/
Frozen robust multiarray 
analysis (fRMA)
R Pre-processing Requires large data set and 
platform limitation 
Free https://www.r-project.org/
P-value meta-analysis Any/R Gene prioritization Significance test only Free https://www.r-project.org/
Fold-change meta-analysis Any/R Gene prioritization Fold-change-based effect size only Free https://www.r-project.org/
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discovery. Hence, publications suggest that a set of biomarker 
that works well for one center or one set of patients based on 
well-conducted statistical methods may not work as well for 
another center or a different set of patients with variable demo-
graphics or other previously unrecognized clinical confounders. 
It is also important to recognize that most of the biomarkers in 
transplantation are still in development, as they do not have the 
support of robust prospective clinical trials. The biomarkers also 
face the challenge of their correlation being based on histology as 
the “gold standard,” a standard that we know is not perfect, as it 
underdiagnoses alloimmune injury and is not really a predictive 
measure. Thus, most of the biomarkers in research are really just 
“associated” with histologic findings. It is still unclear if using 
these biomarkers will ever actually improve graft survival as this 
requires the conduct of large clinical trials with long-term follow-
up, making this research very expensive and often untenable in 
clinical practice; thus, most omic studies are underpowered with 
it comes to predicting graft loss. Biomarkers often do not dictate 
the type of therapy, but accurate prediction of immune risk may 
allow for their use as companion diagnostics for specific drugs 
or for safe immunosuppression minimization. Biomarkers may 
also not always obviate the need for a biopsy, as often they do not 
differentiate between infections such as polyoma and rejection 
as both are associated with graft inflammation. Thus, there may 
still be the need for confirmatory biopsies for the cause or type 
of organ injury.
The fragmented and incomplete nature of the existing knowl-
edge bases poses a challenge to achieving these goals, and wider 
adoption of a policy to submit raw data into public repository 
should be required by the transplant-related journals. It is also 
imperative that the next generation of clinician scientists is armed 
with computational skills that will ensure novel questions contin-
ued to be posed and answered, enabled by the proper integration 
of diverse sources of data.
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